The Scientific and Clinical Team at Immune-Onc Therapeutics is responsible for spearheading the discovery and development of novel myeloid checkpoint inhibitors. This team merges extensive scientific research with clinical expertise to advance innovative cancer immunotherapies through rigorous preclinical and clinical trials, ensuring both efficacy and safety in treating cancer patients.